<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Herz</journal-id><journal-id journal-id-type="iso-abbrev">Herz</journal-id><journal-title-group><journal-title>Herz</journal-title></journal-title-group><issn pub-type="ppub">0340-9937</issn><issn pub-type="epub">1615-6692</issn><publisher><publisher-name>Springer Medizin</publisher-name><publisher-loc>Munich</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27071968</article-id><article-id pub-id-type="pmc">4839058</article-id><article-id pub-id-type="publisher-id">4427</article-id><article-id pub-id-type="doi">10.1007/s00059-016-4427-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Main Topic</subject></subj-group></article-categories><title-group><article-title>Glucose-lowering therapy in type&#x000a0;2 diabetes</article-title><subtitle>New hope after the EMPA-REG outcome trial</subtitle><trans-title-group><trans-title xml:lang="de">Glukosesenkende Therapie bei Typ-2-Diabetes</trans-title><trans-subtitle>Neue Hoffnung nach der EMPA-REG-Wirkungsstudie</trans-subtitle></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Schernthaner</surname><given-names>G.</given-names></name><address><email>guntram.schernthaner@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Schernthaner</surname><given-names>G.-H.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Medical University Vienna, Wien, &#x000d6;sterreich </aff><aff id="Aff2"><label/>Department of Medicine&#x000a0;II, Division of Angiology, Medical University Vienna, Wien, &#x000d6;sterreich </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2016</year></pub-date><volume>41</volume><fpage>208</fpage><lpage>216</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>Prevention of cardiovascular morbidity and mortality remains the key factor in the treatment of type&#x000a0;2 diabetes (T2DM). In the early phase of T2DM, multifactorial intervention is mandatory and glucose levels should be near normal, in particular in younger patients presenting with the highest cardiovascular risk. Anti-diabetic drugs without any risk for hypoglycaemia should be preferred in order to reduce clinical inertia and increase the long-term adherence to the treatment. In patients already presenting with cardiovascular disease, the best outcome may be expected with the triple oral therapy of metformin, pioglitazone, and empagliflozin, although a&#x000a0;controlled prospective study versus insulin therapy is needed to confirm the expectation.</p></abstract><trans-abstract xml:lang="de" id="Abs2"><title>Zusammenfassung</title><p>Die Verhinderung kardiovaskul&#x000e4;rer Ereignisse und des kardiovaskul&#x000e4;ren Todes bleiben die Schl&#x000fc;sselfaktoren bei der Behandlung des Typ-2-Diabetes mellitus. In der Fr&#x000fc;hphase des Diabetes ist eine multifaktorielle Intervention notwendig und der Blutzuckerspiegel sollte ann&#x000e4;hernd normal sein, besonders bei jungen Patienten mit hohem kardiovaskul&#x000e4;ren Risiko. Antidiabetika ohne Hypoglyk&#x000e4;mierisiko sollten bevorzugt warden, um klinische Unt&#x000e4;tigkeit zu reduzieren und die Langzeitadh&#x000e4;renz der Therapie zu erh&#x000f6;hen. Bei Patienten mit bereits vorhandener kardiovaskul&#x000e4;rer Erkrankung wird die beste Wirkung mit einer oralen Tripeltherapie aus Metformin, Pioglitazone und Empagliflozin erwartet, wiewohl eine kontrollierte prospektive Studie mit diesen drei Substanzen im Vergleich zu einer Insulintherapie ben&#x000f6;tigt wird, um diese Erwartung zu best&#x000e4;tigen.</p></trans-abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cardiovascular disease</kwd><kwd>EMPA-REG outcome</kwd><kwd>PROactive</kwd><kwd>Glucose-lowering therapy</kwd><kwd>Type&#x000a0;2 diabetes</kwd></kwd-group><kwd-group xml:lang="de"><title>Schl&#x000fc;sselw&#x000f6;rter</title><kwd>Kardiovaskul&#x000e4;re Erkrankungen</kwd><kwd>EMPA-REG-Outcome-Studie</kwd><kwd>PROactive</kwd><kwd>Antidiabetische Therapie</kwd><kwd>Typ-2-Diabetes</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Medizin Verlag 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>The major cause of death and complications in patients with type&#x000a0;2 diabetes (T2DM) is cardiovascular disease (CVD). More than 60&#x02009;% of all patients with T2DM die of CVD, and an even greater percentage have serious complications [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>The impact of glucose lowering on cardiovascular complications is a&#x000a0;worldwide debated issue. Three major studies (ACCORD, ADVANCE, and VADT) evaluated the impact of attaining euglycemia (ACCORD) or near-euglycemia (ADVANCE, VADT) in older patients with diabetes and high cardiovascular (CV) risk [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. None of these studies, either individually or on pooled analysis, demonstrated any reduction in all-cause or CV mortality, although the meta-analyses revealed 15&#x02013;17&#x02009;% reductions in the incidence of non-fatal myocardial infarction in those exposed to tight glucose control [<xref ref-type="bibr" rid="CR5">5</xref>]. A&#x000a0;higher mortality was observed in the intensive glucose control arm of ACCORD, resulting in the premature termination of the glucose-lowering component of this study [<xref ref-type="bibr" rid="CR2">2</xref>]. Also, the occurrence of hypoglycaemic episodes (total and major) was significantly higher in the intensive glucose control arms of all three studies [<xref ref-type="bibr" rid="CR1">1</xref>]. In addition to hyperglycaemia, patients with T2DM often present with additional risk factors that predispose them to CVD. These include insulin resistance, obesity, hypertension, dyslipidaemia, chronic inflammation, platelet abnormalities, and chronic inflammation [<xref ref-type="bibr" rid="CR6">6</xref>].</p></sec><sec id="Sec2"><title>Recent dramatic decline of all-cause mortality and CV death in T2DM</title><p>During the last 25&#x000a0;years (1976&#x02013;2001) an impressive decline in all-cause (&#x02212;48&#x02009;%) and cardiovascular disease (CVD) mortality (&#x02212;62&#x02009;%) rates among both men and women with diabetes mellitus was observed in the Framingham study versus the period of 1950&#x02013;1975 [<xref ref-type="bibr" rid="CR7">7</xref>]. The implementation of the multifactorial CV risk factor management (blood pressure and lipid lowering) resulted in an enormous improvement in the prognosis of T2DM treated in developed nations (US, EU countries, Canada, Australia). Data from the Danish National Diabetes Register showed that the mortality rate of T2DM patients decreased by 40&#x02009;% from 1997 to 2007 [<xref ref-type="bibr" rid="CR8">8</xref>]. Similarly, the excess mortality of patients with T2DM in Canada (Ontario) and in UK (THIN database), decreased by 44&#x000a0;and 43&#x02009;% respectively from 1996 to 2009 [<xref ref-type="bibr" rid="CR9">9</xref>]. In addition data from Australia showed that the age-standardized mortality rates decreased from 9.4 to 5.5 per 1,000&#x000a0;patient years from 1997&#x02013;2010 [<xref ref-type="bibr" rid="CR10">10</xref>]. However, in many countries both men and women with T2DM continue to remain at a&#x000a0;higher risk of all-cause and CVD mortality than those without DM despite risk-reduction strategies that include lowering of cholesterol and blood pressure, and smoking cessation [<xref ref-type="bibr" rid="CR11">11</xref>].</p></sec><sec id="Sec3"><title>Primary prevention of CVD: relevance of multifactorial intervention including diabetes control</title><p>Unfortunately, we do not have any long-term multifactorial intervention study in newly diagnosed T2DM patients. A&#x000a0;recently published nationwide study [<xref ref-type="bibr" rid="CR12">12</xref>], which included 435,369 patients with T2DM from the Swedish National Diabetes Register and for each patient five controls randomly selected from the general population and matched according to age, sex, and county (total number of controls <italic>n</italic>&#x000a0;= 2,117,483), showed that the excess mortality in T2DM was substantially higher with worsening glycaemic control, severe renal complications, impaired renal function, and younger age. The included patients had the following characteristics: mean age 65.8&#x000a0;years, age at diagnosis of T2DM 60.2&#x000a0;years, 44.9&#x02009;% women, mean BMI: 29.8&#x000a0;kg/m<sup>2</sup> and duration of diabetes 5.6&#x000a0;years. After a&#x000a0;follow-up of 5&#x000a0;years 77,117 of 435,369 patients with T2DM (17.7&#x02009;%) died, as compared with 306,097 of 2,117,483 controls (14.5&#x02009;%) (adjusted HR, 1.15; 95&#x02009;% CI 1.14&#x02013;1.16) [<xref ref-type="bibr" rid="CR12">12</xref>]. The overall excess risk of death from any cause was very low as compared with earlier reports, when the analysis was adjusted for age and sex and the excess risk decreased to 15&#x02009;% when the analysis was further adjusted for coexisting diseases. The relatively low mortality in the Swedish T2DM patients is probably due to aggressive treatment with statins and blood-pressure medications and relatively good diabetes control. Mean blood pressure was 140/78&#x000a0;mmHg, mean HbA1c was 7.1&#x02009;%, and mean LDL was 2.94&#x000a0;mmol/l. The excess risk of death ranged from 30&#x02013;40&#x02009;% among patients 65&#x02013;74&#x000a0;years of age, as compared with controls in the same age group, whereas the excess mortality was 100&#x02013;200&#x02009;% among those younger than 55&#x000a0;years of age, as compared with controls. Remarkably, all-cause mortality (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a) and CV death (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b) were closely related to glycaemic control (HbA1c) in all age groups. However, the relationship was much stronger in younger patients and less pronounced in elderly patients. Remarkably, patients 65&#x02013;74&#x000a0;years of age with normoalbuminuria and an HbA1c of &#x02264;&#x000a0;6.9&#x02009;% had a lower risk than the controls. Similarly, the risk was also lower among patients &#x02265;&#x000a0;75&#x000a0;years of age with an HbA1c of &#x02264;&#x000a0;7.8&#x02009;% than among the controls, but the risk was substantially higher among patients younger than 55&#x000a0;years of age than among the controls, despite an HbA1c level in the target range and normoalbuminuria.<fig id="Fig1"><label>Fig. 1</label><caption><p>
<bold>a</bold>&#x000a0;Death from any cause among patients with T2DM versus controls in relation to age and mean glycated haemoglobin levels. <bold>b</bold>&#x000a0;CV death among patients with T2DM versus controls in relation to age and mean glycated haemoglobin levels. <italic>p</italic>-values for the interaction term between time-updated mean glycated haemoglobin or renal disease status and time-updated age categories were less than 0.001 in all models</p></caption><graphic xlink:href="59_2016_4427_Fig1_HTML" id="d30e295"/></fig></p></sec><sec id="Sec4"><title>Multifactorial risk factor control is less performed in patients without CVD</title><p>A&#x000a0;recent large study [<xref ref-type="bibr" rid="CR13">13</xref>] including about 860,000 patients assessed the incidence of major CV hospitalization events and all-cause deaths among adults with diabetes with or without CVD associated with inadequately controlled diabetes (HbA1c), high LDL-cholesterol (LDL-C), high blood pressure (BP), and current smoking. Inadequate risk factor control was classified as LDL-C &#x02265;&#x000a0;100&#x000a0;mg/dl, HbA1c &#x0003e;&#x000a0;7&#x02009;%, BP &#x02265;&#x000a0;140/90&#x000a0;mmHg, or smoking. Interestingly, compared with those without baseline CVD, those with baseline CVD had better control of smoking (8.0&#x02009;vs. 9.8&#x02009;%), HbA1c &#x02265;&#x000a0;7&#x02009;% (42&#x02009;vs. 53&#x02009;%), and LDL-C &#x02265;&#x000a0;100&#x000a0;mg/dl (38&#x02009;vs. 58&#x02009;%), and they had similar proportions of subjects with systolic/diastolic BP &#x02265;&#x000a0;140/90&#x000a0;mmHg (23 vs. 21&#x02009;%). Mean age at baseline was 59&#x000a0;years; 48&#x02009;% of subjects were female, 45&#x02009;% were white, and 31&#x02009;% had CVD. Mean follow-up was 59&#x000a0;months. Major CV events were based on primary hospital discharge diagnoses for myocardial infarction (MI) and acute coronary syndrome (ACS), stroke, or heart failure (HF). Event rates per 100&#x000a0;person-years for adults with diabetes and CVD versus those without CVD were 6.0 vs. 1.7 for MI/ACS, 5.3 vs. 1.5 for stroke, 8.4 vs. 1.2 for HF, 18.1 vs. 40 for all CV events, and 23.5 vs. 5.0 for all-cause mortality. The percentages of CV events and deaths associated with inadequate risk factor control were 11 and 3&#x02009;%, respectively, for those with CVD but 34&#x000a0;and 7&#x02009;%, respectively, for those without CVD. These data demonstrate that (a)&#x000a0;T2DM patients without CVD are not as well treated for risk factor control and (b)&#x000a0;that the inadequate risk factor control in patients without CVD has a&#x000a0;very negative impact on CV events and death.</p></sec><sec id="Sec5"><title>CV outcome studies with novel anti-diabetic agents in patients with T2DM</title><p>Due to the close association of CVD with T2DM and the uncertainty about the CV safety of glucose-lowering drugs, the Food and Drug Administration issued in 2008 guidance for the demonstration of CV safety for new anti-diabetes drugs [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> summarizes all CV outcomes trials (CVOT), which will be available at the end of the year 2020). At that time all available CVOT studies will include about 180,000 patients with T2DM and CVD followed up with a&#x000a0;novel anti-diabetic drug or placebo in addition to standard care. In the mean time we have for most of the newer glucose-lowering drugs results from CVOT, the PROactive study [<xref ref-type="bibr" rid="CR15">15</xref>] for pioglitazone, the ORIGIN study [<xref ref-type="bibr" rid="CR16">16</xref>] for Insulin Glargine, the SAVOR study [<xref ref-type="bibr" rid="CR17">17</xref>] for Saxagliptin, EXAMINE for Alogliptin [<xref ref-type="bibr" rid="CR18">18</xref>], TECOS for Sitagliptin [<xref ref-type="bibr" rid="CR19">19</xref>] and ELIXA for Lixisenatide [<xref ref-type="bibr" rid="CR20">20</xref>]. The design of these studies makes it almost impossible to show benefits of any novel drug. All patients were at high CV risk and had long-standing uncontrolled T2DM for 8&#x02013;10 years. Treatments that might be effective for the primary prevention of CVD and have potential CV benefits in early intervention may be ineffective in the progressed stage of T2DM. In addition, most patients were receiving standard care treatments for their CVD (antiplatelet agents, including aspirin, 75&#x02013;97&#x02009;%; statins, 78&#x02013;90&#x02009;%; beta-blockers, 62&#x02013;85&#x02009;%; angiotensin converting enzyme inhibitor/ angiotensin receptor blocker, 79&#x02013;85&#x02009;%) so that any potential added CV risk reduction or secondary CVD prevention by a&#x000a0;novel anti-diabetic drug was less likely to be observed. The published results show that most agents, with the exception of pioglitazone and empagliflozin, neither increased nor decreased major adverse CV events (CV death, non-fatal myocardial infarction, and non-fatal stroke) compared with placebo (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Effect of glucose-lowering drugs on the combined endpoint of CV mortality, non-fatal myocardial infarction and stroke</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>Anti-diabetic Drug</th><th>HR</th><th>
<italic>p</italic>-value</th></tr></thead><tbody><tr><td>PROACTIVE</td><td>Pioglitazone</td><td>0.84 (CI 0.72&#x02013;0.98)</td><td>0.02</td></tr><tr><td>ORIGIN</td><td>Insulin Glargine</td><td>1.02 (CI 0.94&#x02013;1.11)</td><td>NS</td></tr><tr><td>SAVOR</td><td>Saxagliptin</td><td>1.00 (CI 0.89&#x02013;1.12)</td><td>NS</td></tr><tr><td>EXAMINE</td><td>Alogliptin</td><td>0.96 (CI 0.80&#x02013;1.15)</td><td>NS</td></tr><tr><td>CANVAS</td><td>Canagliflozin</td><td>1.00 (CI 0.72&#x02013;1.39)</td><td>NS</td></tr><tr><td>ELIXA</td><td>Lixisenatide</td><td>1.02 (CI 0.89&#x02013;1.17)</td><td>NS</td></tr><tr><td>TECOS</td><td>Sitagliptin</td><td>0.98 (CI 0.89&#x02013;1.08)</td><td>NS</td></tr><tr><td>EMPA-REG</td><td>Empagliflozin</td><td>0.86 (CI 0.74&#x02013;0.99)</td><td>0.038</td></tr></tbody></table><table-wrap-foot><p>
<italic>HR</italic>&#x000a0;hazard ratio, <italic>CI</italic>&#x000a0;confidence interval, <italic>NS</italic>&#x000a0;not significant</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>CV outcome studies in patients with T2DM: chronology of completion dates. (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/home">https://clinicaltrials.gov/ct2/home</ext-link>; last accessed May 29, 2015) (SAVOR-TIMI 53, NCT01107886; EXAMINE, NCT00968708; ELIXA, NCT01147250; TECOS, NCT00790205; EMPA-REG-OUTCOME, NCT01131676; LEADER, NCT01179048; SUSTAIN 6, NCT01720446; CANVAS-R, NCT01989754; ACE, NCT00829660 (*<ext-link ext-link-type="uri" xlink:href="https://www.dtu.ox.ac.uk/ace/">https://www.dtu.ox.ac.uk/ace/</ext-link>; last accessed May 29, 2015); CARMELINA, NCT01897532; EXSCEL, NCT01144338; CANVAS, NCT01032629; CAROLINA, NCT01243424; DEVOTE, NCT01959529; TOSCA.IT, NCT00700856; REWIND, NCT01394952; DECLARE-TIMI 58, NCT01730534; CREDENCE, NCT02065791; NCT01986881)</p></caption><graphic xlink:href="59_2016_4427_Fig2_HTML" id="d30e503"/></fig></p><p>Remarkably, a&#x000a0;significant and similar reduction of the three-point MACE (CV death, non-fatal MI, and non-fatal stroke) was found in [<xref ref-type="bibr" rid="CR15">15</xref>] for pioglitazone (HR 0.84; 95&#x02009;% CI 0.72&#x02013;0.98) and for Empagliflozin (HR 0.86; 95&#x02009;% CI 0.74&#x02013;0.99) in the EMPA-REG outcome study [<xref ref-type="bibr" rid="CR21">21</xref>], however with striking differences. In PROactive [<xref ref-type="bibr" rid="CR15">15</xref>] both fatal/nonfatal stroke (HR&#x000a0;= 0.72, <italic>p</italic>&#x000a0;= 0.045) and fatal/nonfatal myocardial infarction (HR&#x000a0;= 0.53, <italic>p</italic>&#x000a0;= 0.008) were markedly reduced, whereas the small reduction of MI and the increase of stroke in EMPA-REG outcome [<xref ref-type="bibr" rid="CR21">21</xref>] did not reach levels of significance. By contrast the impressive reduction of CV&#x000a0;death and all-cause mortality seen in patients exposed to empagliflozin was not seen with pioglitazone.</p></sec><sec id="Sec6"><title>PROactive</title><p>The PROactive study [<xref ref-type="bibr" rid="CR15">15</xref>] was a&#x000a0;large prospective, randomized, double-blind, secondary prevention study that investigated the effects of pioglitazone (45&#x000a0;mg/day) on macrovascular outcomes in 5,238 patients with T2DM and pre-existing CVD: ~&#x000a0;50&#x02009;% with previous MI, 25&#x02009;% with previous stroke, and 25&#x02009;% with peripheral arterial disease (PAD). Treatment with pioglitazone or placebo was administered in addition to optimized standard care, which included glucose lowering, antihypertensive, lipid-altering, and antithrombotic drugs. Although the primary end point &#x02013; a&#x000a0;composite of all-cause mortality, non-fatal MI, acute coronary syndrome, stroke, major leg amputation, and coronary or leg revascularization &#x02013; showed only a&#x000a0;nonsignificant 10&#x02009;% reduction in the pioglitazone arm, a&#x000a0;significant reduction in a&#x000a0;composite end point, comprising CV death plus non-fatal MI plus non-fatal stroke, was observed (HR 0.82 [95&#x02009;% CI 0.70&#x02013;0.97]) in the 3-year follow-up period [<xref ref-type="bibr" rid="CR15">15</xref>]. Furthermore, in patients with a&#x000a0;previous MI, pioglitazone significantly reduced the risk of subsequent MI by 28&#x02009;% and acute coronary syndrome by 38&#x02009;% [<xref ref-type="bibr" rid="CR22">22</xref>]. In patients with a&#x000a0;previous stroke, pioglitazone decreased chances of a&#x000a0;second stroke by 48&#x02009;% [<xref ref-type="bibr" rid="CR23">23</xref>], whereas in patients with PAD no beneficial effect of pioglitazone could be noted [<xref ref-type="bibr" rid="CR24">24</xref>]. It is well known that diabetic patients with chronic kidney disease (CKD) are at particularly high risk of CVD. In a&#x000a0;post hoc analysis from PROactive, the effect of pioglitazone versus placebo was determined in patients with CKD [<xref ref-type="bibr" rid="CR25">25</xref>]. Patients treated with pioglitazone were less likely to reach the composite (all-cause mortality, MI, or stroke) end point (HR 0.66 [95&#x02009;% CI 0.45&#x02013;0.98]) compared with placebo. In addition, two randomized head-to-head trials with glimepiride have shown that pioglitazone significantly decreased the rate of carotid intima thickness, a&#x000a0;surrogate marker of coronary atherosclerosis [<xref ref-type="bibr" rid="CR26">26</xref>] and slowed the progression of coronary atherosclerosis measured by IVUS [<xref ref-type="bibr" rid="CR27">27</xref>]. The anti-atherogenic effect of pioglitazone may be mediated by the improvement of many CV risk factors [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], such as increase in HDL-cholesterol, decline of triglycerides and free fatty acids (FFA), conversion of small dense LDL particles to larger, more buoyant, less atherogenic ones; improvement of endothelial dysfunction; increase of adiponectin and reduction of PAI-1, CRP, and TNF&#x003b1;, and reduction of insulin resistance and visceral fat.</p><p>The clinical use of pioglitazone is limited by the risk of adverse events, including weight gain, fluid retention, CHF and bone fractures [<xref ref-type="bibr" rid="CR30">30</xref>]. In the PROactive study [<xref ref-type="bibr" rid="CR15">15</xref>] 5.7 and 4.1&#x02009;% of pioglitazone and placebo patients, respectively, were admitted to hospital [<xref ref-type="bibr" rid="CR31">31</xref>]; however, mortality rates due to CHF were similar (0.96 vs. 0.84&#x02009;%; <italic>p</italic>&#x000a0;= NS). Interestingly, fewer pioglitazone patients with serious CHF had a&#x000a0;combined end point of death, MI, or stroke compared with placebo patients (34.9 vs. 47.2&#x02009;%; <italic>p</italic>&#x000a0;= 0.025). Since heart failure is an ominous sign in T2DM with a&#x000a0;five-year mortality of ~&#x000a0;50&#x02009;%, it is unlikely that these individuals really had CHF. It is more likely that they had fluid retention and oedema secondary to the sodium retention effect of pioglitazone in the kidney. Concern about bladder cancer with pioglitazone has been negated by the results of a 10-year prospective Kaiser-Permanente Northern-California study [<xref ref-type="bibr" rid="CR32">32</xref>]. In that safety study involving 193,099 T2DM patients, no association was found between bladder cancer risk and use of pioglitazone, including duration of pioglitazone use, cumulative pioglitazone dose, or time since initiation of pioglitazone. A&#x000a0;further study [<xref ref-type="bibr" rid="CR33">33</xref>] including 1.01 million T2DM patients with over 5.9 million person-years from six&#x000a0;populations, reported no increased risk for bladder cancer either for pioglitazone (HR&#x000a0;= 1.01) or rosiglitazone (HR&#x000a0;= 1.00).</p></sec><sec id="Sec7"><title>EMPA-REG outcome</title><p>The recently published EMPA-REG outcome trial [<xref ref-type="bibr" rid="CR21">21</xref>] is an international, prospective, placebo-controlled clinical trial investigating the cardiovascular outcomes of empagliflozin, an inhibitor of sodium-glucose cotransporters type&#x000a0;2 (SGLT2), in patients with T2DM and known CVD. It is the first study to document that a&#x000a0;glucose-lowering drug can reduce cardiovascular events in patients with T2DM. In 7020 T2DM patients with a&#x000a0;history of CVD, empagliflozin reduced, after a&#x000a0;median of 3.1 years, the primary MACE endpoint (CV death, non-fatal MI, non-fatal stroke) by 14&#x02009;% (HR&#x000a0;= 0.86, <italic>p</italic>&#x000a0;= 0.04) and hospitalization for heart failure by 35&#x02009;% (HR&#x000a0;= 0.65, <italic>p</italic>&#x000a0;= 0.002). A&#x000a0;striking difference was observed between the three MACE endpoints: (a)&#x000a0;for CV death, the HR (0.62) was decreased significantly by 38&#x02009;%, (b)&#x000a0;for non-fatal MI, the HR (0.87) was decreased slightly, but not significantly (<italic>p</italic>&#x000a0;= 0.22) and (c)&#x000a0;for stroke, the HR (1.24) was increased modestly, but not significantly (<italic>p</italic>&#x000a0;= 0.22). Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> shows the impressive effects of empagliflozin on the absolute risk reduction of CV events in the EMPA-REG outcome study. The reduction in CV death (5.9 to 3.6&#x02009;%, <italic>p</italic> &#x0003c;&#x000a0;0.001) was observed across all diagnostic categories (sudden death, 1.6 to 1.1&#x02009;%; worsening heart failure, 0.8 to 0.2&#x02009;%; acute MI, 0.5 to 0.3&#x02009;%; stroke, 0.5 to 0.3&#x02009;%; &#x0201c;other CV death&#x0201d;, 2.4 to 1.6&#x02009;%). The latter category includes deaths that cannot be explained by any other known cause. The reduction in mortality appeared very early (&#x0003c;&#x000a0;3&#x000a0;months) and was observed in all subgroups, without any obvious heterogeneity. This reduction in mortality does not seem to be fully explained by the concomitant slight reductions in HbA1c, body weight, waist circumference, blood pressure, and serum uric acid levels in the empagliflozin groups versus the placebo group. The rapid reduction of mortality in empagliflozin-treated patients suggests a&#x000a0;hemodynamic mechanism of action. The baseline BP (135.5/76.7&#x000a0;mmHg) was significantly reduced at 4&#x000a0;months (~&#x000a0;5/2.5&#x000a0;mmHg), and temporarily correlated with the reduction in CV death and hospitalization for heart failure. A&#x000a0;recent study [<xref ref-type="bibr" rid="CR34">34</xref>] showed that empagliflozin reduced not only BP but had also favourable effects on markers of arterial stiffness and vascular resistance. The observation that empagliflozin has an impact on the vasculature without increasing pulse rate is interesting from a&#x000a0;CV perspective and could be interpreted as a&#x000a0;consequence of a&#x000a0;relative reduction in the sympathetic nervous system tonus. It seems likely that the beneficial effects of empagliflozin to reduce CV risk and heart failure are related to the drug&#x02019;s hemodynamic/cardiovascular action to reduce BP and intravascular volume, resulting in combined afterload and preload reduction.<fig id="Fig3"><label>Fig. 3</label><caption><p>Significant Improvement of CV outcomes by Empagliflozin. <italic>HR</italic>&#x000a0;hazard ratio. Indicated with 95&#x02009;% confidence intervals; <italic>ARR</italic>&#x000a0;Absolute risk reduction</p></caption><graphic xlink:href="59_2016_4427_Fig3_HTML" id="d30e629"/></fig></p><p>Surprisingly, an impressive renoprotection was also observed [<xref ref-type="bibr" rid="CR35">35</xref>] although 26&#x02009;% of the patients with CVD also had CKD (eGFR &#x0003c;&#x000a0;60), usually not receiving SGLT2 inhibitors. New onset or worsening kidney disease were reduced by 39&#x02009;%, new macro-albuminuria by 38&#x02009;%, doubling of serum creatinine by 44&#x02009;%, and incidence of end-stage renal disease by 55&#x02009;%. It is important to mention that the majority of patients with CKD at baseline had stage&#x000a0;3a (68&#x02009;%), whereas stage&#x000a0;3b existed in 32&#x02009;%, furthermore all patients with CKD stages&#x000a0;4 and 5 were excluded from the EMPA-REG outcome study.</p><p>The EMPA-REG study also confirms the excellent safety profile of the SGLT2 inhibitor (SGLT2i) class of
anti-diabetic agents. Empagliflozin significantly reduced HbA1c, body weight, waist circumference, and blood pressure
without change in heart rate. There was no increase in the incidence of hypoglycaemia despite half of the patients were
pre-treated with insulin, renal impairment, urinary tract infections, volume-related side effects, bone fractures, or
thromboembolic events. Furthermore, the rate of hyperglycaemic or normoglycaemic diabetic ketoacidosis was very low and
not higher in patients exposed to empagliflozin (0.035&#x02009;%) versus placebo (0.020&#x02009;%). Serious adverse events and adverse events leading to drug discontinuation were slightly, although not significantly lower in the empagliflozin group. As expected, the incidence of genital infections was higher in the empagliflozin group (6.4&#x02009;%) vs. placebo (1.8&#x02009;%).</p></sec><sec id="Sec8"><title>Individualization of anti-diabetic therapy in relation to stage of the disease and co-morbidity</title><p>The ADA-EASD consensus statement published in 2009 [<xref ref-type="bibr" rid="CR36">36</xref>] advocated initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a&#x000a0;sulfonylurea if glycaemic goals are not met (tier&#x000a0;1 recommendations). All other glucose-lowering therapies were relegated to a&#x000a0;secondary (tier&#x000a0;2) status and only recommended for selected clinical settings. The approach that all patients should have the same HbA1c target (&#x0003c;&#x000a0;7.0&#x02009;%) and that all patients should follow an identical treatment algorithm was heavily criticised by an international expert group [<xref ref-type="bibr" rid="CR37">37</xref>]. We argued for an appropriate selection of anti-diabetic drugs to individualise and optimise care with a&#x000a0;view to sustained control of blood glucose and reduction both of diabetes complications and CV risk. In addition, we stated that diabetes guidelines might need revision to define a&#x000a0;minimum HbA1c value, especially for patients with long-standing diabetes or established CVD. The ADA-EASD consensus statements 2012 [<xref ref-type="bibr" rid="CR38">38</xref>] and 2015 [<xref ref-type="bibr" rid="CR39">39</xref>] included most of our proposals.</p><p>Patients not presenting with vascular complications should have near-normoglycaemic control in association with strict CVD risk factor control as documented in the recently published Swedish population study [<xref ref-type="bibr" rid="CR12">12</xref>]. In particular, younger patients with a&#x000a0;poor long-term risk need HbA1c target levels &#x0003c;&#x000a0;6.5&#x02009;%, which can be reached when glucose-lowering drugs are selected not inducing hypoglycaemia or weight gain. Metformin remains the optimal drug for monotherapy, its low cost, proven safety record, weight reduction or neutrality and possible benefits on cardiovascular outcomes have secured its place as the favoured initial drug choice [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. In second line, DPP-4 inhibitors are now widely used, since these drugs are well tolerated by the majority of patients, even in the elderly and renal-impaired patients [<xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. DPP-4 inhibitors improve glycaemic control with similar efficacy to sulphonylurea, but do not usually provoke hypoglycaemia or weight gain, are relatively free from adverse effects, and have recently been shown not to increase CV risk in large prospective safety trials. Because of these factors, DPP-4 inhibitors have become an established therapy for T2DM and are increasingly being positioned earlier in treatment algorithms [<xref ref-type="bibr" rid="CR39">39</xref>]. When sulfonylureas are used with respect to very low cost, Gliclazide should be preferred versus other sulfonylureas based on the lower risk for hypoglycaemia and better CV safety profile [<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]. The glucose-lowering potency is very similar for most of the anti-diabetic drugs when starting at a HbA1c level of about 8&#x02009;% [<xref ref-type="bibr" rid="CR51">51</xref>], however when HbA1c values are higher Insulin, GLP-1 receptor agonists, or SGLT2-inhibitors are more powerful than DPP-4 inhibitors and sulfonylureas [<xref ref-type="bibr" rid="CR52">52</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>].</p><p>In T2DM patients already presenting with CVD, principally all drugs (DPP-4 inhibitors, GLP-1 receptor agonists, and basal insulin glargine) with confirmed safety in outcome studies [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>] could be used, however in order to reduce CV events and CV death, a combination of drugs should be preferred with documented CV benefit. The triple combination of metformin, pioglitazone, and empagliflozin seems to be at the moment the best option (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) to reduce the high risk for recurrent myocardial infarction, acute coronary syndrome or stroke in patients with a&#x000a0;history of CVD [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. In addition, such a&#x000a0;combination would result in reduction of CV death and all-cause mortality by about one third [<xref ref-type="bibr" rid="CR21">21</xref>]. This triple combination would be very effective in lowering HbA1c by different mechanisms &#x02013; reduction of hepatic glucose production, improvement of insulin sensitivity and by the glucoretic effect [<xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>] &#x02013; but not inducing any risk of hypoglycaemia and offering weight neutrality. The profound effect of lowering of both BP and albuminuria &#x02013; mediated by different mechanism &#x02013; may be helpful to reduce the vascular burden of the high risk patients [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. This triple combination could also be used in patients with CKD stages&#x000a0;3 and 4, since a&#x000a0;significant reduction of CV events/mortality was documented for all three&#x000a0;compounds, for metformin [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>], pioglitazone [<xref ref-type="bibr" rid="CR25">25</xref>], and empagliflozin [<xref ref-type="bibr" rid="CR35">35</xref>]. In the presence of heart failure pioglitazone has to be stopped [<xref ref-type="bibr" rid="CR31">31</xref>], although the well-known water retention effect of pioglitazone may be neutralized by empagliflozin (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> shows that (a)&#x000a0;some positive or negative effects of the three individual &#x000a0;drugs may be neutralized in combination; and (b)&#x000a0;in addition some positive effects could also work synergistically. Unfortunately, no study will ever be done to prove our treatment concept for diabetic patients already presenting with CVD. Since in some but not in all studies DPP-4 inhibitors were associated with an increased the risk for heart failure [<xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR66">66</xref>], these compounds may also not be used in patients with concomitant occurrence of CVD and heart failure. A&#x000a0;recent study showed that the risk for heart failure is particularly high in the presence of CKD [<xref ref-type="bibr" rid="CR67">67</xref>], thus patients with CVD, CKD and heart failure should be treated with SGLT2 inhibitors but not with DPP-4 inhibitors [<xref ref-type="bibr" rid="CR66">66</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>Anticipated combinatory effect of metformin, pioglitazone, and empagliflozin</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Metformin</th><th>Pioglitazone</th><th>Empagliflozin</th><th>Anticipated effect?</th></tr></thead><tbody><tr><td>Cardiovascular death</td><td>&#x02193;</td><td>&#x02194;</td><td>&#x02193;&#x02193;</td><td>&#x02193;&#x02193;&#x02193;</td></tr><tr><td>All-cause death</td><td>&#x02193;</td><td>&#x02194;</td><td>&#x02193;&#x02193;</td><td>&#x02193;&#x02193;&#x02193;</td></tr><tr><td>Myocardial infarction</td><td>&#x02193;</td><td>&#x02193;</td><td>&#x02194;</td><td>&#x02193;&#x02193;</td></tr><tr><td>Stroke</td><td>&#x02193;</td><td>&#x02193;</td><td>&#x02194;</td><td>&#x02193;&#x02193;</td></tr><tr><td>Peripheral arterial disease</td><td>&#x02193;</td><td>&#x02194;</td><td>&#x02194;</td><td>&#x02193;</td></tr><tr><td>Fluid retention</td><td>&#x02194;</td><td>&#x02191;</td><td>&#x02193;</td><td>&#x02194;</td></tr><tr><td>Heart failure</td><td>&#x02194;</td><td>&#x02191;</td><td>&#x02193;</td><td>&#x02194;</td></tr><tr><td>Weight</td><td>&#x02193;</td><td>&#x02191;</td><td>&#x02193;</td><td>&#x02193;</td></tr><tr><td>Blood pressure</td><td>&#x02194;</td><td>&#x02193;</td><td>&#x02193;</td><td>&#x02193;&#x02193;</td></tr><tr><td>HbA1c</td><td>&#x02193;</td><td>&#x02193;</td><td>&#x02193;</td><td>&#x02193;&#x02193;&#x02193;</td></tr><tr><td>LDL-cholesterol</td><td>&#x02193;</td><td>&#x02194;</td><td>&#x02191;</td><td>&#x02194;</td></tr><tr><td>HDL-cholesterol</td><td>&#x02194;</td><td>&#x02191;</td><td>&#x02191;</td><td>&#x02191;&#x02191;</td></tr><tr><td>Albuminuria</td><td>&#x02194;</td><td>&#x02193;</td><td>&#x02193;</td><td>&#x02193;&#x02193;</td></tr><tr><td>Insulin sensitivity</td><td>&#x02191;</td><td>&#x02191;&#x02191;</td><td>&#x02191;</td><td>&#x02191;&#x02191;&#x02191;&#x02191;</td></tr></tbody></table><table-wrap-foot><p>&#x02193;&#x000a0;lowered, &#x02191;&#x000a0;elevated, &#x02194;&#x000a0;unchanged</p></table-wrap-foot></table-wrap></p><p>In summary, prevention of CV morbidity and mortality remains to be the key factor in the treatment of T2DM. In the early phase of T2DM multifactorial intervention is mandatory and glucose levels should be near normal, in particular in the younger patients presenting with the highest long-term CV risk. Anti-diabetic drugs without any risk for hypoglycaemia should be preferred in order to reduce clinical inertia and increase long-term adherence to the treatment. Two very recent studies [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>] are not in favour of a&#x000a0;wide use of sulfonylureas or insulin. In a&#x000a0;nationwide study [<xref ref-type="bibr" rid="CR68">68</xref>] using Taiwan&#x02019;s National Health Insurance Research Database, DPP-4 inhibitors were associated with lower risks for all-cause death (HR 0.63 [95&#x02009;% CI 0.55&#x02013;0.72]), MACE (HR, 0.68 [95 %CI 0.55&#x02013;0.83]), ischemic stroke (HR, 0.64 [95 %CI 0.51&#x02013;0.81]), and hypoglycaemia (HR, 0.43 [95 %CI 0.33&#x02013;0.56]) compared with sulfonylureas as add-on therapy to metformin but had no effect on risks for myocardial infarction and hospitalization for heart failure. A&#x000a0;recent meta-analysis [<xref ref-type="bibr" rid="CR69">69</xref>] of randomized controlled trials evaluating the effects of insulin versus oral hypoglycaemic agents (OHAs) on all-cause mortality and CV outcomes in patients with T2DM did not show any superiority for insulin therapy concerning all-cause mortality (RR&#x000a0;= 1.00; 95&#x02009;% CI 0.93&#x02013;1.07), CV death (RR&#x000a0;= 1.00; 95&#x02009;% CI 0.91&#x02013;1.09), myocardial infarction (RR&#x000a0;= 1.04; 95&#x02009;% CI 0.93&#x02013;1.16), angina (RR&#x000a0;= 0.97; 95&#x02009;% CI 0.88&#x02013;1.06), sudden death (RR&#x000a0;= 1.02; 95&#x02009;% CI 0.66&#x02013;1.56), or stroke (RR&#x000a0;= 1.01; 95&#x02009;% CI 0.88&#x02013;1.15). However, insulin reduced the risk of heart failure compared with OHAs (RR&#x000a0;= 0.87; 95&#x02009;% CI 0.75&#x02013;0.99). In the very high risk subgroup of secondary prevention of CVD insulin did not differ from OHAs in all-cause mortality, CV death, myocardial infarction, or stroke.</p><p>In patients presenting with CVD the best outcome may be expected with the triple oral therapy of metformin, pioglitazone and empagliflozin, although a&#x000a0;controlled prospective study versus insulin therapy is needed to confirm the expectation.</p><p>Our recommendation for the inclusion of pioglitazone in the triple therapy in diabetic patients with a history of CVD is strongly supported by recent findings of the IRIS study [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>], where pioglitazone or placebo were added to nondiabetic patients after ischaemic stroke or TIA. After a treatment period of 4.8 years pioglitazone prevented stroke or myocardial infarction by 24 % relative risk reduction and by 2.9 % absolute risk reduction (<italic>p</italic> &#x0003c; 0.007), despite the fact that the patients were well treated according to current guidelines (antiplatelet drugs in 95 %, statins in 82 %); blood pressure values were 133/79 mmHg and LDL values 89 mg/dl. In the insulin-resistant nondiabetic patients diabetes developed in 7,7 % of the patients receiving placebo, but in only 3.8 % under pioglitazone (58 % relative risk reduction, <italic>p</italic> &#x0003c; 0.001). Incidence of heart failure or incident cancer were not increased in patients receiving pioglitazone, but there was more weight gain (plus 3 kg) and bone fractures under pioglitazone compared with placebo (5.1 vs. 3.2 %, <italic>p</italic> = 0.01). Since two thirds of nondiabetic patients with CVD and almost all patients with overt diabetes are insulin resistant, these data show for the first time that a therapy directed to insulin resistance can prevent cardiac and cerebrovascular events and has important clinical consequences.</p></sec></body><back><notes notes-type="conflict-interest"><title>Compliance with ethical guidelines</title><sec id="FPar1"><title>Conflict of interest</title><p>G.&#x000a0;Schernthaner reports receiving fees for global/EU/ national advisory meetings from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Sanofi-Aventis, Servier and Takeda and honoraria for lectures for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Servier and Takeda. G.-H.&#x000a0;Schernthaner reports receiving fees for advisory meetings from AstraZeneca, Boehringer Ingelheim, Bristol-Meyers-Squibb, honoraria for lectures from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Meyers-Squibb, Servier, Sanofi-Aventis and Takeda.</p><p>The accompanying manuscript does not include studies on humans or animals.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name></person-group><article-title>Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from aCCORD, aDVaNCE, VaDT, UKPDS, PROactive, and NICE-SUGaR</article-title><source>Wien Med Wochenschr</source><year>2010</year><volume>160</volume><fpage>8</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1007/s10354-010-0748-7</pub-id><pub-id pub-id-type="pmid">20229156</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Miller</surname><given-names>ME</given-names></name><name><surname>Byington</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2545</fpage><lpage>2559</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0802743</pub-id><pub-id pub-id-type="pmid">18539917</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><etal/></person-group><article-title>ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2560</fpage><lpage>2572</lpage><pub-id pub-id-type="doi">10.1056/NEJMicm066227</pub-id><pub-id pub-id-type="pmid">18539916</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duckworth</surname><given-names>W</given-names></name><name><surname>Abraira</surname><given-names>C</given-names></name><name><surname>Moritz</surname><given-names>T</given-names></name><etal/></person-group><article-title>Intensive glucose control and complications in american veterans with type 2 diabetes</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0808431</pub-id><pub-id pub-id-type="pmid">19092145</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JA</given-names></name><name><surname>Bowker</surname><given-names>SL</given-names></name></person-group><article-title>Intensive glycaemic control and cancer risk in type 2 diabetes: a meta analysis of major trials</article-title><source>Diabetologia</source><year>2011</year><volume>54</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1007/s00125-010-1933-3</pub-id><pub-id pub-id-type="pmid">20959956</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>GH</given-names></name><name><surname>Schernthaner</surname><given-names>G</given-names></name></person-group><article-title>Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention</article-title><source>Scand J Clin Lab Invest Suppl</source><year>2005</year><volume>240</volume><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1080/00365510500236119</pub-id><pub-id pub-id-type="pmid">16112958</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preis</surname><given-names>SR</given-names></name><name><surname>Hwang</surname><given-names>SJ</given-names></name><name><surname>Coady</surname><given-names>S</given-names></name></person-group><article-title>Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005.</article-title><source>Circulation</source><year>2009</year><volume>119</volume><fpage>1728</fpage><lpage>1735</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.829176</pub-id><pub-id pub-id-type="pmid">19307472</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carstensen</surname><given-names>B</given-names></name><name><surname>Kristensen</surname><given-names>JK</given-names></name><name><surname>Ottosen</surname><given-names>P</given-names></name><etal/></person-group><article-title>The danish national diabetes register: trends in incidence, prevalence and mortality</article-title><source>Diabetologia</source><year>2008</year><volume>51</volume><fpage>2187</fpage><lpage>2196</lpage><pub-id pub-id-type="doi">10.1007/s00125-008-1156-z</pub-id><pub-id pub-id-type="pmid">18815769</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lind</surname><given-names>M</given-names></name><name><surname>Garcia-Rodriguez</surname><given-names>LA</given-names></name><name><surname>Booth</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study</article-title><source>Diabetologia</source><year>2013</year><volume>56</volume><fpage>2601</fpage><lpage>2608</lpage><pub-id pub-id-type="doi">10.1007/s00125-013-3063-1</pub-id><pub-id pub-id-type="pmid">24114114</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>JL</given-names></name><name><surname>Shaw</surname><given-names>JE</given-names></name><name><surname>Peeters</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997&#x02013;2010</article-title><source>Diabetes Care</source><year>2014</year><volume>37</volume><fpage>2579</fpage><lpage>2588</lpage><pub-id pub-id-type="doi">10.2337/dc14-0096</pub-id><pub-id pub-id-type="pmid">24947787</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarwar</surname><given-names>N</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Seshasai</surname><given-names>SR</given-names></name><collab>Emerging Risk Factors Collaboration</collab></person-group><article-title>Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>2215</fpage><lpage>2222</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60484-9</pub-id><pub-id pub-id-type="pmid">20609967</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tancredi</surname><given-names>M</given-names></name><name><surname>Rosengren</surname><given-names>A</given-names></name><name><surname>Svensson</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Excess mortality among persons with type 2 diabetes</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>1720</fpage><lpage>1732</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1504347</pub-id><pub-id pub-id-type="pmid">26510021</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vazquez-Benitez</surname><given-names>G</given-names></name><name><surname>Desai</surname><given-names>JR</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><fpage>905</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.2337/dc14-1877</pub-id><pub-id pub-id-type="pmid">25710922</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirshberg</surname><given-names>B</given-names></name><name><surname>Katz</surname><given-names>A</given-names></name></person-group><article-title>Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><issue>Suppl 2</issue><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.2337/dcS13-2041</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dormandy</surname><given-names>JA</given-names></name><name><surname>Charbonnel</surname><given-names>B</given-names></name><name><surname>Eckland</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>1279</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67528-9</pub-id><pub-id pub-id-type="pmid">16214598</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trial Investigators</surname><given-names>ORIGIN</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><etal/></person-group><article-title>Basal insulin and cardiovascular and other outcomes in dysglycemia</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>319</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1203858</pub-id><pub-id pub-id-type="pmid">22686416</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scirica</surname><given-names>BM</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><etal/></person-group><article-title>Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>1317</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1307684</pub-id><pub-id pub-id-type="pmid">23992601</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Heller</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Alogliptin after acute coronary syndrome in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>1327</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1305889</pub-id><pub-id pub-id-type="pmid">23992602</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>JB</given-names></name><name><surname>Bethel</surname><given-names>MA</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1501352</pub-id><pub-id pub-id-type="pmid">26052984</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Claggett</surname><given-names>B</given-names></name><name><surname>Diaz</surname><given-names>R</given-names></name><etal/></person-group><article-title>Lixisenatide in patients with type 2 diabetes and acute coronary syndrome</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>2247</fpage><lpage>2257</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1509225</pub-id><pub-id pub-id-type="pmid">26630143</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinman</surname><given-names>B</given-names></name><name><surname>Wanner</surname><given-names>C</given-names></name><name><surname>Lachin</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>2117</fpage><lpage>2128</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1504720</pub-id><pub-id pub-id-type="pmid">26378978</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdmann</surname><given-names>E</given-names></name><name><surname>Dormandy</surname><given-names>JA</given-names></name><name><surname>Charbonnel</surname><given-names>B</given-names></name><etal/></person-group><article-title>The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>49</volume><fpage>1772</fpage><lpage>1780</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2006.12.048</pub-id><pub-id pub-id-type="pmid">17466227</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcox</surname><given-names>R</given-names></name><name><surname>Bousser</surname><given-names>MG</given-names></name><name><surname>Betteridge</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)</article-title><source>Stroke</source><year>2007</year><volume>38</volume><fpage>865</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000257974.06317.49</pub-id><pub-id pub-id-type="pmid">17290029</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dormandy</surname><given-names>JA</given-names></name><name><surname>Betteridge</surname><given-names>DJ</given-names></name><name><surname>Schernthaner</surname><given-names>G</given-names></name><etal/></person-group><article-title>Impact of peripheral arterial disease in patients with diabetes results from PROactive (PROactive 11)</article-title><source>Atherosclerosis</source><year>2009</year><volume>202</volume><fpage>272</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2008.03.002</pub-id><pub-id pub-id-type="pmid">18538774</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>CA</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Defronzo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1681/ASN.2007060678</pub-id><pub-id pub-id-type="pmid">18057215</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzone</surname><given-names>T</given-names></name><name><surname>Meyer</surname><given-names>PM</given-names></name><name><surname>Feinstein</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial</article-title><source>JAMA</source><year>2006</year><volume>296</volume><fpage>2572</fpage><lpage>2581</lpage><pub-id pub-id-type="doi">10.1001/jama.296.21.joc60158</pub-id><pub-id pub-id-type="pmid">17101640</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Wolski</surname><given-names>K</given-names></name><etal/></person-group><article-title>Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial</article-title><source>JAMA</source><year>2008</year><volume>299</volume><fpage>1561</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.1001/jama.299.13.1561</pub-id><pub-id pub-id-type="pmid">18378631</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name></person-group><article-title>Pleiotropic effects of thiazolidinediones on traditional and nontraditional atherosclerotic risk factors</article-title><source>Int J Clin Pract</source><year>2009</year><volume>63</volume><fpage>912</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2009.02025.x</pub-id><pub-id pub-id-type="pmid">19490202</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFronzo</surname><given-names>RA</given-names></name></person-group><article-title>Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009</article-title><source>Diabetologia</source><year>2010</year><volume>53</volume><fpage>1270</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1007/s00125-010-1684-1</pub-id><pub-id pub-id-type="pmid">20361178</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Currie</surname><given-names>CJ</given-names></name><name><surname>Schernthaner</surname><given-names>GH</given-names></name></person-group><article-title>Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><issue>Suppl 2</issue><fpage>S155</fpage><lpage>S161</lpage><pub-id pub-id-type="doi">10.2337/dcS13-2031</pub-id><pub-id pub-id-type="pmid">23882041</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdmann</surname><given-names>E</given-names></name><name><surname>Charbonnel</surname><given-names>B</given-names></name><name><surname>Wilcox</surname><given-names>RG</given-names></name></person-group><article-title>Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>2773</fpage><lpage>2778</lpage><pub-id pub-id-type="doi">10.2337/dc07-0717</pub-id><pub-id pub-id-type="pmid">17666462</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JD</given-names></name><name><surname>Habel</surname><given-names>LA</given-names></name><name><surname>Quesenberry</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes</article-title><source>JAMA</source><year>2015</year><volume>314</volume><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.7996</pub-id><pub-id pub-id-type="pmid">26197187</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>D</given-names></name><name><surname>Bell</surname><given-names>S</given-names></name><name><surname>Sund</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis</article-title><source>Diabetologia</source><year>2015</year><volume>58</volume><fpage>493</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1007/s00125-014-3456-9</pub-id><pub-id pub-id-type="pmid">25481707</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chilton</surname><given-names>R</given-names></name><name><surname>Tikkanen</surname><given-names>I</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes</article-title><source>Diabetes Obes Metab</source><year>2015</year><volume>17</volume><fpage>1180</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1111/dom.12572</pub-id><pub-id pub-id-type="pmid">26343814</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanner</surname><given-names>C</given-names></name><name><surname>Lachin</surname><given-names>JM</given-names></name><name><surname>Fitchett</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Empagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease</article-title><source>J Am Soc Nephrol</source><year>2015</year><volume>26</volume><issue>Suppl B1</issue><fpage>1133</fpage></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Davidson</surname><given-names>MB</given-names></name><etal/></person-group><article-title>(2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.2337/dc08-9025</pub-id><pub-id pub-id-type="pmid">18945920</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Barnett</surname><given-names>AH</given-names></name><name><surname>Betteridge</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis</article-title><source>Diabetologia</source><year>2010</year><volume>53</volume><fpage>1258</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1007/s00125-010-1702-3</pub-id><pub-id pub-id-type="pmid">20352408</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzucchi</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. position statement of the american diabetes association (aDa) and the european association for the study of diabetes (EaSD)</article-title><source>Diabetologia</source><year>2012</year><volume>55</volume><fpage>1577</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1007/s00125-012-2534-0</pub-id><pub-id pub-id-type="pmid">22526604</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzucchi</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><fpage>140</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.2337/dc14-2441</pub-id><pub-id pub-id-type="pmid">25538310</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Schernthaner</surname><given-names>GH</given-names></name></person-group><article-title>Metformin &#x02013; From Devil to Angel</article-title><source>Pharmacotherapy of Diabetes: New Developments</source><year>2008</year><publisher-loc>&#x025a0;</publisher-loc><publisher-name>CE Mogensen</publisher-name><fpage>77</fpage><lpage>86</lpage></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>CJ</given-names></name></person-group><article-title>Metformin: effects on micro and macrovascular complications in type 2 diabetes</article-title><source>Cardiovasc Drugs Ther</source><year>2008</year><volume>22</volume><fpage>215</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1007/s10557-008-6092-0</pub-id><pub-id pub-id-type="pmid">18288595</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Charbonnel</surname><given-names>B</given-names></name><etal/></person-group><article-title>Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>6068</fpage><lpage>6076</lpage><pub-id pub-id-type="doi">10.1210/jc.2003-030861</pub-id><pub-id pub-id-type="pmid">15579760</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Lebovitz</surname><given-names>HE</given-names></name></person-group><article-title>A comparative review of DPP&#x02011;4 inhibitors and Sulphonylureas</article-title><source>Diabetes Obes Metab</source><year>2015</year><volume>&#x025a0;</volume><fpage>&#x025a0;</fpage></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Barnett</surname><given-names>AH</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged &#x02265; 65 years</article-title><source>Diabetes Obes Metab</source><year>2014</year><volume>16</volume><fpage>1078</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1111/dom.12321</pub-id><pub-id pub-id-type="pmid">24865132</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groop</surname><given-names>PH</given-names></name><name><surname>Del Prato</surname><given-names>S</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment</article-title><source>Diabetes Obes Metab</source><year>2014</year><volume>16</volume><fpage>560</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1111/dom.12281</pub-id><pub-id pub-id-type="pmid">24612167</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Dur&#x000e1;n-Garcia</surname><given-names>S</given-names></name><name><surname>Hanefeld</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)</article-title><source>Diabetes Obes Metab</source><year>2015</year><volume>17</volume><fpage>630</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1111/dom.12461</pub-id><pub-id pub-id-type="pmid">25761977</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Grimaldi</surname><given-names>A</given-names></name><name><surname>Di Mario</surname><given-names>U</given-names></name><etal/></person-group><article-title>GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients</article-title><source>Eur J Clin Invest</source><year>2004</year><volume>34</volume><fpage>535</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.2004.01381.x</pub-id><pub-id pub-id-type="pmid">15305887</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schramm</surname><given-names>TK</given-names></name><name><surname>Gislason</surname><given-names>GH</given-names></name><name><surname>Vaag</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><fpage>1900</fpage><lpage>1908</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehr077</pub-id><pub-id pub-id-type="pmid">21471135</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelmoneim</surname><given-names>AS</given-names></name><name><surname>Eurich</surname><given-names>DT</given-names></name><name><surname>Gamble</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study</article-title><source>Diabetes Obes Metab</source><year>2014</year><volume>16</volume><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1111/dom.12173</pub-id><pub-id pub-id-type="pmid">23802997</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mortality risk among sulfonylureas: a systematic review and network meta-analysis</article-title><source>Lancet Diabetes Endocrinol</source><year>2015</year><volume>3</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(14)70213-X</pub-id><pub-id pub-id-type="pmid">25466239</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>JL</given-names></name><name><surname>Kramer</surname><given-names>CK</given-names></name><name><surname>Leit&#x000e3;o</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis</article-title><source>Ann Intern Med</source><year>2011</year><volume>154</volume><fpage>672</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-154-10-201105170-00007</pub-id><pub-id pub-id-type="pmid">21576535</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>K</given-names></name><name><surname>Chiodini</surname><given-names>P</given-names></name><name><surname>Bellastella</surname><given-names>G</given-names></name><etal/></person-group><article-title>Proportion of patients at HbA1c target</article-title><source>Diabetes Obes Metab</source><year>2012</year><volume>14</volume><fpage>228</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2011.01512.x</pub-id><pub-id pub-id-type="pmid">21958121</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Russell-Jones</surname><given-names>D</given-names></name><etal/></person-group><article-title>Is insulin the most effective injectable antihyperglycaemic therapy?</article-title><source>Diabetes Obes Metab</source><year>2015</year><volume>17</volume><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1111/dom.12402</pub-id><pub-id pub-id-type="pmid">25323312</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name><name><surname>Rosenstock</surname><given-names>J</given-names></name><etal/></person-group><article-title>Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>2508</fpage><lpage>2515</lpage><pub-id pub-id-type="doi">10.2337/dc12-2491</pub-id><pub-id pub-id-type="pmid">23564919</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prager</surname><given-names>R</given-names></name><name><surname>Schernthaner</surname><given-names>G</given-names></name></person-group><article-title>Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance following metformin treatment. Results of a double-blind cross-over study in type II diabetics</article-title><source>Diabetes</source><year>1983</year><volume>32</volume><fpage>1083</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.2337/diab.32.12.1083</pub-id><pub-id pub-id-type="pmid">6360756</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prager</surname><given-names>R</given-names></name><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Graf</surname><given-names>H</given-names></name></person-group><article-title>Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus</article-title><source>Diabetes Metab</source><year>1986</year><volume>12</volume><fpage>346</fpage><lpage>350</lpage></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natali</surname><given-names>A</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name></person-group><article-title>Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>434</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1007/s00125-006-0141-7</pub-id><pub-id pub-id-type="pmid">16477438</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdul-Ghani</surname><given-names>MA</given-names></name><name><surname>Norton</surname><given-names>L</given-names></name><name><surname>Defronzo</surname><given-names>RA</given-names></name></person-group><article-title>Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes</article-title><source>Endocr Rev</source><year>2011</year><volume>32</volume><fpage>515</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1210/er.2010-0029</pub-id><pub-id pub-id-type="pmid">21606218</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Mogensen</surname><given-names>CE</given-names></name><name><surname>Schernthaner</surname><given-names>GH</given-names></name></person-group><article-title>The effects of GLP-1 analogues, DPP&#x02011;4 inhibitors and SGLT2 inhibitors on the renal system</article-title><source>Diab Vasc Dis Res</source><year>2014</year><volume>11</volume><fpage>306</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1177/1479164114542802</pub-id><pub-id pub-id-type="pmid">25116004</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussel</surname><given-names>R</given-names></name><name><surname>Travert</surname><given-names>F</given-names></name><name><surname>Pasquet</surname><given-names>B</given-names></name><etal/></person-group><article-title>Reduction of Atherothrombosis for continued health (REaCH) registry investigators. Metformin use and mortality among patients with diabetes and atherothrombosis</article-title><source>Arch Intern Med</source><year>2010</year><volume>170</volume><fpage>1892</fpage><lpage>1899</lpage><pub-id pub-id-type="doi">10.1001/archinternmed.2010.409</pub-id><pub-id pub-id-type="pmid">21098347</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Schernthaner-Reiter</surname><given-names>MH</given-names></name></person-group><article-title>Risk of metformin use in patients with T2DM and advanced CKD</article-title><source>Nat Rev Endocrinol</source><year>2015</year><volume>11</volume><fpage>697</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2015.132</pub-id><pub-id pub-id-type="pmid">26284445</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scirica</surname><given-names>BM</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Raz</surname><given-names>I</given-names></name><etal/></person-group><article-title>Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial</article-title><source>Circulation</source><year>2014</year><volume>130</volume><fpage>1579</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.010389</pub-id><pub-id pub-id-type="pmid">25189213</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>DL</given-names></name><name><surname>McAlister</surname><given-names>FA</given-names></name><name><surname>Senthilselvan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study</article-title><source>JACC Heart Fail</source><year>2014</year><volume>2</volume><fpage>573</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1016/j.jchf.2014.04.005</pub-id><pub-id pub-id-type="pmid">24998080</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zannad</surname><given-names>F</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial</article-title><source>Lancet</source><year>2015</year><volume>385</volume><fpage>2067</fpage><lpage>2076</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)62225-X</pub-id><pub-id pub-id-type="pmid">25765696</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>AZ</given-names></name><name><surname>Johnston</surname><given-names>SS</given-names></name><name><surname>Ghannam</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association between hospitalization for heart failure and Dipeptidyl Peptidase-4 inhibitors in patients with type 2 diabetes: an observational study</article-title><source>Diabetes Care</source><year>2016</year><volume>6</volume><fpage>&#x025a0;</fpage></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G</given-names></name><name><surname>Cahn</surname><given-names>A</given-names></name><name><surname>Raz</surname><given-names>I</given-names></name></person-group><article-title>Is the use of DPP&#x02011;4 inhibitors associated with an increased risk for heart failure &#x02013; lessons from SAVOR, EXAMINE and TECOS</article-title><source>Diabetes Care</source><year>2016</year><volume>&#x025a0;</volume><fpage>&#x025a0;</fpage></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udell</surname><given-names>JA</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><etal/></person-group><article-title>Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><fpage>696</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">25552421</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>SM</given-names></name><name><surname>Shih</surname><given-names>CJ</given-names></name><name><surname>Chao</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Effects on clinical outcomes of adding Dipeptidyl Peptidase-4 inhibitors versus Sulfonylureas to Metformin therapy in patients with type 2 diabetes mellitus</article-title><source>Ann Intern Med</source><year>2015</year><volume>163</volume><fpage>663</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.7326/M15-0308</pub-id><pub-id pub-id-type="pmid">26457538</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effects on All-Cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-Analysis of Randomized Controlled Trials</article-title><source>Clin Ther</source><year>2016</year><volume>7</volume><fpage>&#x025a0;</fpage></element-citation></ref><ref id="CR70"><label>70.</label><mixed-citation publication-type="other">Viscoli CM, Brass LM, Carolei A et al (2014) Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J 168:823&#x02013;829</mixed-citation></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="other">Kernan WN, Viscoli CM, Furie KL et al (2016) Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. doi: 10.1056/NEJMoa1506930</mixed-citation></ref></ref-list></back></article>